BetterLife Pharma Inc.
Recent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- BetterLife Pharma Inc. (CSE:BETR) is a biotechnology company focused on developing and commercializing non-hallucinogenic psychedelic derivatives and related compounds to treat neuro-psychiatric, neurological disorders and viral infections. The company offers BETR-001 (2-bromo-LSD or E559), a proprietary oral capsule second-generation LSD derivative in IND-enabling studies for major depressive disorder, anxiety disorder, neuropathic pain, treatment-resistant depression, PTSD, cluster headaches, traumatic brain injury and migraines; BETR-002 (dihydrohonokiol-B or DHH-B), an oral capsule derivative of hydrohonokiol targeting benzodiazepine dependency, anxiety and neurodegenerative disorders; and interferon-based candidates including MM-003, which completed Phase II trials for COVID-19 and respiratory viral infections, and MM-001, a topical cream that completed Phase II trials for HPV-induced cervical intraepithelial neoplasia, through its wholly owned subsidiary MedMelior Pharmaceuticals Inc. BetterLife Pharma Inc. was founded in 2002, changed its name from Pivot Pharmaceuticals Inc. in December 2019, and maintains headquarters at 1275 West 6th Avenue, Suite 300, Vancouver, British Columbia, Canada V6H 1A6. The company conducts operations and strategic relationships in Canada, the United States and Switzerland, with common shares listed on the Canadian Securities Exchange, OTCQB and Frankfurt exchanges. Recent developments include closing private placements and convertible debentures totaling approximately $1.168 million to advance BETR-001 development; appointing Daniel Carcillo, a traumatic brain injury survivor and advocate, as corporate advisor on November 25, 2025, to support BETR-001 indications in TBI, cluster headaches and migraines; and advancing IND-enabling studies and presentations at conferences such as the 2024 Bloom Burton & Co. Healthcare Investor Conference.
Company News
BetterLife Pharma Appoints Professor Richard B. Lipton as Co-Chair of its Scientific Advisory Board
BetterLife Pharma Appoints Sheila Leitzinger as Head of Clinical Operations
BetterLife Pharma Inc. (OTCMKTS:BETRF) Stock Short Interest Report for September
BetterLife Pharma Establishes Scientific Advisory Board for Headache Program; Professor Peter Goadsby Appointed Co-Chair
BetterLife Pharma Addresses Notice of Civil Claim Filed by Steven Sangha
BetterLife Pharma Announces Rescheduling and Reclassification of Annual General Meeting to Annual General and Special Meeting
BetterLife Pharma Inc. (OTCMKTS:BETRF) Sees Large Decrease in Short Interest
BetterLife Pharma Inc. Announces Closing of US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Inc. Announces Filing of Final Prospectus for US$100 Million Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Appoints Charles Duncan as Director and Chair of the Audit Committee
BetterLife Pharma Inc. Announces Proposed Public Offering of Common Shares and Pre-Funded Warrants
BetterLife Pharma Appoints Mahan Chehrenama, DO, as Chief Medical Officer
BetterLife Pharma Prioritizes BETR-001 to Lead in Migraine and Headache Disorders, Targeting a Clinically Validated, FDA-Precedented Serotonergic Mechanism
BetterLife Engages Nucro-Technics to Complete the last GLP Toxicology Study of BETR-001 Required by the FDA for IND and Phase 1
BetterLife Engages Syner-G to Oversee GMP Manufacturing of BETR-001 for IND and Phase 1
BetterLife Pharma Secures CAD $2 Million in New Capital to Complete BETR-001 FDA IND Filing
BetterLife Pharma Announces Appointment of Doug Drysdale as Executive Chairman and Director
BetterLife Pharma to Participate in YAFO Capital Access Asia Partnering Forum During JPM Week in San Francisco
BetterLife Pharma Highlights Advantages of BETR-001 -- a Potent Neuroplastogen
BetterLife Pharma Welcomes Daniel Carcillo as Corporate Advisor